Paladin Labs Files New Drug Submission for Oralair
Paladin Labs Inc., a Canadian specialty pharmaceutical company, announced today that it has filed a new drug submission for Oralair with Health Canada. Oralair is a sublingual grass pollen immunotherapy tablet for the treatment of grass pollen rhinitis with or without conjunctivitis for patients uncontrolled with current symptomatic medications.
The current standard of care for grass allergy sufferers - multiple injections of grass allergens performed in a doctor's office - is very cumbersome for the patients. In addition, one of the potential side effects of such injections is anaphylactic shock. This can be compared to Oralair, which is a sublingual tablet and can be taken in the comfort of one's own home. Oralair has an unmatched safety profile with no severe adverse event reported. Unlike subcutaneous immunotherapy treatments, Oralair efficacy is documented with seven placebo controlled clinical trials involving more than 2,500 patients.
"In short we are excited for Canadian allergy sufferers to have an efficacious, safer and more convenient treatment option." said Jonathan Ross Goodman, President & CEO of Paladin Labs.